DIVISLAB's weekly return of -3.97% was a disappointing performance, with high volatility of 25.8%. Although it outperformed DRREDDY and CIPLA, it underperformed SUNPHARMA. The stock's Sharpe Ratio of -0.61 indicates a poor risk-return tradeoff, and its Max Drawdown of -3.97% suggests a significant decline in value. Overall, DIVISLAB was a relatively risky investment this week.

[Volatility: 25.8%]